How to use type 2 diabetes meds to lower CV disease risk

The challenge: Translate evidence from cardiovascular outcomes trials of newer antidiabetic agents into a targeted management strategy.

The association between type 2 diabetes (T2D) and cardiovascular (CV) disease is well-established:

- Type 2 diabetes approximately doubles the risk of coronary artery disease, stroke, and peripheral arterial disease, independent of conventional risk factors.\(^1\)
- CV disease is the leading cause of morbidity and mortality in patients with T2D.\(^2\)

In recent years, new classes of agents for treating T2D have been introduced (TABLE 1). Prior to 2008, the US Food and Drug Administration (FDA) approved drugs in those new classes based simply on their effectiveness in reducing the blood glucose level. Concerns about the CV safety of specific drugs (eg, rosiglitazone, muraglitazar) emerged from a number of trials, suggesting that these agents might increase the risk of CV events.\(^3,4\)

Consequently, in 2008, the FDA issued guidance to the pharmaceutical industry: Preapproval and postapproval trials of all new antidiabetic drugs must now assess potential excess CV risk.\(^5\) CV outcomes trials (CVOTs), performed in accordance with FDA guidelines, have therefore become the focus of evaluating novel treatment options. In most CVOTs, combined primary CV endpoints have included CV mortality, nonfatal myocardial infarction (MI), and nonfatal stroke—taken together, what is known as the composite of these 3 major adverse CV events, or MACE-3.

To date, 15 CVOTs have been completed, assessing 3 novel classes of antihyperglycemic agents:

- dipeptidyl peptidase-4 (DPP-4) inhibitors
- glucagon-like peptide-1 (GLP-1) receptor agonists
- sodium–glucose cotransporter-2 (SGLT-2) inhibitors.

None of these trials identified any increased incidence of MACE; 7 found CV benefit. This review summarizes what the

---

**PRACTICE RECOMMENDATIONS**

> Consider American Diabetes Association (ADA) guidance and prescribe a sodium–glucose cotransporter-2 (SGLT-2) inhibitor or glucagon-like peptide-1 (GLP-1) receptor agonist that has demonstrated cardiovascular (CV) disease benefit for your patients who have type 2 diabetes (T2D) and established atherosclerotic CV disease. \(^A\)

> Consider ADA’s recommendation for preferred therapy and prescribe an SGLT-2 inhibitor for your patients with T2D who have atherosclerotic CV disease and are at high risk of heart failure or in whom heart failure coexists. \(^C\)

---

**Strength of recommendation (SOR)**

- \(^A\) Good-quality patient-oriented evidence
- \(^B\) Inconsistent or limited-quality patient-oriented evidence
- \(^C\) Consensus, usual practice, opinion, disease-oriented evidence, case series

---

Robert Gotfried, DO, FAAFP
Department of Family Medicine, University of Toledo College of Medicine, Ohio
robert.gotfried@utoledo.edu

The authors reported no potential conflict of interest relevant to this article.

The author has lectured on behalf of Pfizer and KOS/Abbott. He has participated in clinical trials for Bristol-Myers Squibb, Novo Nordisk, AstraZeneca, KOS/Abbott, Novartis, and Janssen. He has wholly declined compensation from pharmaceutical and medical device manufacturers.
CVOTs revealed about these antihyperglycemic agents and their ability to yield a reduction in MACE and a decrease in all-cause mortality in patients with T2D and elevated CV disease risk. Armed with this information, you will have the tools you need to offer patients with T2D CV benefit while managing their primary disease.

**Cardiovascular outcomes trials: DPP-4 inhibitors**

**Four trials.** Trials of DPP-4 inhibitors that have been completed and reported are of saxagliptin (SAVOR-TIMI 53), alogliptin (EXAMINE), sitagliptin (TECOS), and linagliptin (CARMELINA); others are in progress. In general, researchers enrolled patients at high risk for developing CV events and compared DPP-4 inhibitors with placebo or other antihyperglycemic agents. The four completed trials are listed in Table 1.

TABLE 1

<table>
<thead>
<tr>
<th>Newer agents for treating type 2 diabetes</th>
<th>Generic name</th>
<th>Brand name(s)</th>
<th>Manufacturer</th>
<th>Trial</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dipeptidyl peptidase-4 inhibitors</strong></td>
<td>Alogliptin</td>
<td>Nesina</td>
<td>Takeda</td>
<td>EXAMINE</td>
</tr>
<tr>
<td></td>
<td>Linagliptin</td>
<td>Tradjenta</td>
<td>Boehringer Ingelheim-Lilly</td>
<td>CARMELINA</td>
</tr>
<tr>
<td></td>
<td>Saxagliptin</td>
<td>Onglyza</td>
<td>AstraZeneca</td>
<td>SAVOR-TIMI 53</td>
</tr>
<tr>
<td></td>
<td>Sitagliptin</td>
<td>Januvia</td>
<td>Merck</td>
<td>TECOS</td>
</tr>
<tr>
<td><strong>Glucagon-like peptide-1 receptor agonists</strong></td>
<td>Albiglutide</td>
<td>Tanzeum</td>
<td>GlaxoSmithKline</td>
<td>HARMONY</td>
</tr>
<tr>
<td></td>
<td>Dulaglutide</td>
<td>Trulicity</td>
<td>Eli Lilly</td>
<td>REWIND</td>
</tr>
<tr>
<td></td>
<td>Exenatide</td>
<td>Byetta/Bydureon</td>
<td>AstraZeneca</td>
<td>EXSEL</td>
</tr>
<tr>
<td></td>
<td>Liraglutide</td>
<td>Victoza</td>
<td>Novo Nordisk</td>
<td>LEADER</td>
</tr>
<tr>
<td></td>
<td>Lixisenatide</td>
<td>Adlyxin</td>
<td>Sanofi-Aventis</td>
<td>ELIXA</td>
</tr>
<tr>
<td></td>
<td>Semaglutide</td>
<td>Ozempic</td>
<td>Novo Nordisk</td>
<td>SUSTAIN-6</td>
</tr>
<tr>
<td><strong>Sodium–glucose cotransporter-2 inhibitors</strong></td>
<td>Canagliflozin</td>
<td>Invokana</td>
<td>Janssen</td>
<td>CANVAS</td>
</tr>
<tr>
<td></td>
<td>Dapagliflozin</td>
<td>Farxiga</td>
<td>AstraZeneca</td>
<td>DECLARE-TIMI 58</td>
</tr>
<tr>
<td></td>
<td>Empagliflozin</td>
<td>Jardiance</td>
<td>Boehringer Ingelheim-Lilly</td>
<td>EMPA-REG OUTCOME</td>
</tr>
</tbody>
</table>

Combination-agent brands are shown in *italics*.  
*Combination with metformin.  
*Combination with pioglitazone.  
*Combination with empagliflozin.  
*Combination with dapagliflozin.  
*Discontinued in the United States.  
*EXSEL studied exenatide in its once-weekly form (sold as Bydureon).  
*Combination with linagliptin.

All glucose-lowering medications used to treat type 2 diabetes are not equally effective in reducing CV complications.
It’s likely that the CV benefits result from mechanisms other than a reduction in the serum glucose level, given the short time frame of the studies and the magnitude of the CV benefit.

Cardiovascular outcomes trials: GLP-1 receptor agonists

I ELIXA. The CV safety of GLP-1 receptor agonists has been evaluated in several randomized clinical trials. The Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial was the first\(^9\): Lixisenatide was studied in 6068 patients with recent hospitalization for acute coronary syndrome. Lixisenatide therapy was neutral with regard to CV outcomes, which met the primary endpoint: noninferiority to placebo \((P < .001)\). There was no increase in either HF or HHF.

**LEADER.** The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results trial (LEADER) evaluated long-term effects of liraglutide, compared to placebo, on CV events in patients with T2D.\(^15\)

It was a multicenter, double-blind, placebo-controlled study that followed 9340 participants, most (81\%) of whom had established CV disease, over 5 years. LEADER is considered a landmark study because it was the first large CVOT to show significant benefit for a GLP-1 receptor agonist.

Liraglutide demonstrated reductions in first occurrence of death from CV causes, nonfatal MI or nonfatal stroke, overall CV mortality, and all-cause mortality. The composite MACE-3 showed a relative risk reduction (RRR) of 13\%, equivalent to an absolute risk reduction (ARR) of 1.9\% (noninferiority, \(P < .001\); superiority, \(P < .01\)). The RRR was 22\% for death from CV causes, with an ARR of 1.3\% \((P = .007)\); the RRR for death from any cause was 15\%, with an ARR of 1.4\% \((P = .02)\).

In addition, there was a lower rate of nephropathy (1.5 events for every 100 patient-years in the liraglutide group \((P = .003)\), compared with 1.9 events every 100 patient-years in the placebo group).\(^15\)

Results clearly demonstrated benefit. No significant difference was seen in the liraglutide rate of HHF, compared to the rate in the placebo group.

**SUSTAIN-6.** Evidence for the CV benefit of GLP-1 receptor agonists was also demonstrated in the phase 3 Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN-6).\(^16\) This was a study of 3297 patients with T2D at high risk of CV disease and with a mean hemoglobin \(A_1C\) (HbA\(_1c\)) value of 8.7\%, 83\% of whom had established CV disease. Patients were randomized to semaglutide or placebo. Note: SUSTAIN-6 was a noninferiority safety study; as such, it was not actually designed to assess or establish superiority.
The incidence of MACE-3 was significantly reduced among patients treated with semaglutide \((P=0.02)\) after median follow-up of 2.1 years. The expanded composite outcome (death from CV causes, nonfatal MI, nonfatal stroke, coronary revascularization, or hospitalization for unstable angina or HF), also showed a significant reduction with semaglutide \((P=0.002)\), compared with placebo. There was no difference in the overall hospitalization rate or rate of death from any cause.

**EXCEL.** The Exenatide Study of Cardiovascular Event Lowering trial (EXCEL)\(^{17,18}\) was a phase III/IV, double-blind, pragmatic placebo-controlled study of 14,752 patients at any level of CV risk, for a median 3.2 years. The study population was intentionally more diverse than in earlier GLP-1 receptor agonist studies. The researchers hypothesized that patients at increased risk of MACE would experience a comparatively greater relative treatment benefit with exenatide than those at lower risk. That did not prove to be the case.

EXCEL did confirm noninferiority compared with placebo \((P<0.001)\), but once-weekly exenatide resulted in a nonsignificant reduction in major adverse CV events, and a trend for RRR in all-cause mortality \((\text{RRR}=14\%; \text{ARR}=1\% \ [P=0.06])\).

**HARMONY OUTCOMES.** The Albiglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Cardiovascular Disease study (HARMONY OUTCOMES)\(^{19}\) was a double-blind, randomized, placebo-controlled trial conducted at 610 sites across 28 countries. The study investigated albiglutide, 30 to 50 mg once weekly, compared with placebo. It included 9463 patients ages ≥ 40 years with T2D who had an HbA\(_1c\) > 7% (median value, 8.7%) and established CV disease. Patients were evaluated for a median 1.6 years.

Albiglutide reduced the risk of CV causes of death, nonfatal MI, and nonfatal stroke by an RRR of 22%, \((\text{ARR}=2\%)\) (noninferiority, \(P<.0001\); superiority, \(P<.0006\)).

**REWIND.** The Researching Cardiovascular Events with a Weekly INcretin in Diabetes trial (REWIND),\(^{20}\) the most recently completed GLP-1 receptor agonist CVOT (presented at the 2019 American Diabetes Association [ADA] Conference in June and published simultaneously in *The Lancet*), was a multicenter, randomized, double-blind placebo-controlled trial designed to assess the effect of weekly dulaglutide, 1.5 mg, compared with placebo, in 9901 participants enrolled at 371 sites in 24 countries. Mean patient age was 66.2 years, with women constituting 4589 (46.3%) of participants.

REWIND was distinct from other CVOTs in several ways:

- Other CVOTs were designed to show noninferiority compared with placebo regarding CV events; REWIND was designed to establish superiority
- In contrast to trials of other GLP-1 receptor agonists, in which most patients had established CV disease, only 31% of REWIND participants had a history of CV disease or a prior CV event (although 69% did have CV risk factors without underlying disease)
- REWIND was much longer (median follow-up, 5.4 years) than other GLP-1 receptor agonist trials (median follow-up, 1.5 to 3.8 years).

In REWIND, the primary composite outcome of MACE-3 occurred in 12% of participants assigned to dulaglutide, compared with 13.1% assigned to placebo \((P=0.026)\). This equated to 2.4 events for every 100 person-years on dulaglutide, compared with 2.7 events for every 100 person-years on placebo. There was a consistent effect on all MACE-3 components, although the greatest reductions were observed in nonfatal stroke \((P=0.017)\). Overall risk reduction was the same for primary and secondary prevention cohorts \((P=.97)\), as well as in patients with either an HbA\(_1c\) value < 7.2% or ≥ 7.2% \((P=.75)\). Risk reduction was consistent across age, sex, duration of T2D, and body mass index.

Dulaglutide did not significantly affect the incidence of all-cause mortality, heart failure, revascularization, or hospital admission. Forty-seven percent of patients taking dulaglutide reported gastrointestinal adverse effects \((P=.0001)\).

In a separate analysis of secondary outcomes,\(^{21}\) dulaglutide reduced the composite renal outcomes of new-onset macroalbuminuria.
In October, the FDA approved dapagliflozin to reduce the risk of hospitalization for heart failure in adults with T2D and established CV disease.

Cardiovascular outcomes trials: SGLT-2 inhibitors

**EMPA-REG OUTCOME.** The Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes trial (EMPA-REG OUTCOME) was also a landmark study because it was the first dedicated CVOT to show that an antihyperglycemic agent 1) decreased CV mortality and all-cause mortality, and 2) reduced HHF in patients with T2D and established CV disease.21 In this trial, 7020 patients with T2D who were at high risk of CV events were randomized and treated with empagliflozin, 10 or 25 mg, or placebo, in addition to standard care, and were followed for a median 2.6 years.

Compared with placebo, empagliflozin resulted in an RRR of 14% (ARR, 1.6%) in the primary endpoint of CV death, nonfatal MI, and stroke, confirming study drug superiority ($P = .04$). When compared with placebo, the empagliflozin group had an RRR of 38% in CV mortality, (ARR < 2.2%) ($P < .001$); an RRR of 35% in HHF (ARR, 1.4%) ($P = .002$); and an RRR of 32% (ARR, 2.6%) in death from any cause ($P < .001$).

**CANVAS.** The Canagliflozin Cardiovascular Assessment Study (CANVAS) integrated 2 multicenter, placebo-controlled, randomized trials with 10,142 participants and a mean follow-up of 3.6 years.23 Patients were randomized to receive canagliflozin (100-300 mg/d) or placebo. Approximately two-thirds of patients had a history of CV disease (therefore representing secondary prevention); one-third had CV risk factors only (primary prevention).

In CANVAS, patients receiving canagliflozin had a risk reduction in MACE-3, establishing superiority compared with placebo ($P < .001$). There was also a significant reduction in progression of albuminuria ($P < .05$). Superiority was not shown for the secondary outcome of death from any cause.

Canagliflozin had no effect on the primary endpoint (MACE-3) in the subgroup of participants who did not have a history of CV disease. Similar to what was found with empagliflozin in EMPA-REG OUTCOME, CANVAS participants had a reduced risk of HHF.

Patients on canagliflozin unexpectedly had an increased incidence of amputations (6.3 participants, compared with 3.4 participants, for every 1000 patient-years). This finding led to a black box warning for canagliflozin about the risk of lower-limb amputation.

**DECLARE-TIMI 58.** The Dapagliflozin Effect of Cardiovascular Events-Thrombolysis in Myocardial Infarction 58 trial (DECLARE-TIMI 58) was the largest SGLT-2 inhibitor outcomes trial to date, enrolling 17,160 patients with T2D who also had established CV disease or multiple risk factors for atherosclerotic CV disease. The trial compared dapagliflozin, 10 mg/d, and placebo, following patients for a median 4.2 years.24 Unlike CANVAS and EMPA-REG OUTCOME, DECLARE-TIMI 58 included CV death and HHF as primary outcomes, in addition to MACE-3.

Dapagliflozin was noninferior to placebo with regard to MACE-3. However, its use did result in a lower rate of CV death and HHF by an RRR of 17% (ARR, 1.9%). Risk reduction was greatest in patients with HF who had a reduced ejection fraction (ARR = 9.2%).25

In October, the FDA approved dapagliflozin to reduce the risk of HHF in adults with T2D and established CV disease or multiple CV risk factors. Before initiating the drug, physicians should evaluate the patient’s renal function and monitor periodically.

Meta-analyses of SGLT-2 inhibitors

**Systematic review.** Usman et al released a meta-analysis in 2018 that included 35 randomized, placebo-controlled trials (including EMPA-REG OUTCOME, CANVAS, and DECLARE-TIMI 58) that had assessed the use of SGLT-2 inhibitors in nearly 35,000 patients with T2D.26 This review concluded that, as a class, SGLT-2 inhibitors reduce all-cause mortality, major adverse cardiac events, nonfatal MI, and HF and HHF, compared with placebo.
When planning T2D pharmacotherapy, include newer agents that offer CV benefit\(^{33-38}\)

**First-line management.** The 2019 Standards of Medical Care in Diabetes Guidelines established by the American Diabetes Association (ADA) recommend metformin as first-line pharmacotherapy for type 2 diabetes (T2D).\(^{33}\) This recommendation is based on metformin's efficacy in reducing the blood glucose level and hemoglobin A\(_1c\) (HbA\(_1c\)); safety; tolerability; extensive clinical experience; and findings from the UK Prospective Diabetes Study demonstrating a substantial beneficial effect of metformin on cardiovascular (CV) disease.\(^{34}\) Additional benefits of metformin include a decrease in body weight, low-density lipoprotein level, and the need for insulin.

**Second-line additive benefit.** In addition, ADA guidelines make a highest level (Level-A) recommendation that patients with T2D and established atherosclerotic CV disease be treated with one of the sodium–glucose cotransporter-2 (SGLT-2) inhibitors or glucagon-like peptide-1 (GLP-1) receptor agonists that have demonstrated efficacy in CV disease risk reduction as part of an antihyperglycemic regimen.\(^{35}\) Seven agents described in this article from these 2 unique classes of medications meet the CV disease benefit criterion: liraglutide, semaglutide, albiglutide, dulaglutide, empagliflozin, canagliflozin, and dapagliflozin. Only empagliflozin and liraglutide have received a US Food and Drug Administration indication for risk reduction in major CV events in adults with T2D and established CV disease.

Regarding dulaglutide, although the findings of REWIND are encouraging, results were not robust; further analysis is necessary to make a recommendation for treating patients who do not have a history of established CV disease with this medication.

**Individualized decision-making.** From a clinical perspective, patient-specific considerations and shared decision-making should be incorporated into T2D treatment decisions:

- For patients with T2D and established atherosclerotic CV disease, SGLT-2 inhibitors and GLP-1 receptor agonists are recommended agents after metformin.
- SGLT-2 inhibitors are preferred in T2D patients with established CV disease and a history of heart failure.
- GLP-1 receptor agonists with proven CV disease benefit are preferred in patients with established CV disease and chronic kidney disease.

**Add-on Tx.** In ADA guidelines, dipeptidyl peptidase-4 (DDP-4) inhibitors are recommended as an optional add-on for patients without clinical atherosclerotic CV disease who are unable to reach their Hba\(_1c\) goal after taking metformin for 3 months.\(^{33}\) Furthermore, the American Association of Clinical Endocrinologists lists DPP-4 inhibitors as alternatives for patients with an Hba\(_1c\) < 7.5% in whom metformin is contraindicated.\(^{36}\) DPP-4 inhibitors are not an ideal choice as a second agent when the patient has a history of heart failure, and should not be recommended over GLP-1 receptor agonists or SGLT-2 inhibitors as second-line agents in patients with T2D and CV disease.

**Individualizing management.** The current algorithm for T2D management,\(^{37}\) based primarily on Hba\(_1c\) reduction, is shifting toward concurrent attention to reduction of CV risk (FIGURE\(^{38}\)). Our challenge, as physicians, is to translate the results of recent CV outcomes trials into a more targeted management strategy that focuses on eligible populations.

---

**FIGURE**

Proposed simplified\(^{a}\) algorithm for patients with T2D and established cardiovascular disease\(^{38}\)

- Provide monotherapy with metformin when the hemoglobin A\(_1c\) value is above goal.
- Select a second agent that has been proven to reduce the impact of cardiovascular disease: ie, a SGLT-2 inhibitor or a GLP-1 receptor agonist (a decision guided by shared decision-making)\(^{b,c}\)
- Patient is in heart failure:
  - SGLT-2 inhibitor (preferred)
  - Use caution if the patient has a history of recurrent genital infection or amputation, or is at risk of amputation or diabetic ketoacidosis; avoid SGLT-2 inhibitors when the patient has chronic kidney disease

- Patient has chronic kidney disease:
  - GLP-1 receptor agonist (preferred)
  - Use caution if the patient has a history of pancreatitis or heart failure; GLP-1 receptor agonists are contraindicated when the patient has a history of medullary thyroid (C-cell) cancer

GLP-1, glucagon-like peptide-1; SGLT-2, sodium-glucose cotransporter-2; T2D, type 2 diabetes.

\(^a\)Modification (simplification) proposed by the author from Davies MJ, et al (2018).\(^{38}\)

\(^b\)Dipeptidyl peptidase-4 inhibitors have not been proven to improve CV outcomes.

\(^c\)Avoid saxagliptin in patients with heart failure.
CVD-REAL. A separate study, Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors (CVD-REAL), of 154,528 patients who were treated with canagliflozin, dapagliflozin, or empagliflozin, showed that initiation of SGLT-2 inhibitors, compared with other glucose-lowering therapies, was associated with a 39% reduction in HHF; a 51% reduction in death from any cause; and a 46% reduction in the composite of HHF or death (P < .001).27 CVD-REAL was unique because it was the largest real-world study to assess the effectiveness of SGLT-2 inhibitors on HHF and mortality. The study utilized data from patients in the United States, Norway, Denmark, Sweden, Germany, and the United Kingdom, based on information obtained from medical claims, primary care and hospital records, and national registries that compared patients who were either newly started on an SGLT-2 inhibitor or another glucose-lowering drug. The drug used by most patients in the trial was canagliflozin (53%), followed by dapagliflozin (42%), and empagliflozin (5%). In this meta-analysis, similar therapeutic effects were seen across countries, regardless of geographic differences, in the use of specific SGLT-2 inhibitors, suggesting a class effect. Of particular significance was that most (87%) patients enrolled in CVD-REAL did not have prior CV disease. Despite this, results for examined outcomes in CVD-REAL were similar to what was seen in other SGLT-2 inhibitor trials that were designed to study patients with established CV disease.

Risk of adverse effects of newer antidiabetic agents

DPP-4 inhibitors. Alogliptin and sitagliptin carry a black-box warning about potential risk of HF. In SAVOR-TIMI, a 27% increase was detected in the rate of HHF after approximately 2 years of saxagliptin therapy.6 Although HF should not be considered a class effect for DPP-4 inhibitors, patients who have risk factors for HF should be monitored for signs and symptoms of HF. Cases of acute pancreatitis have been reported in association with all DPP-4 inhibitors available in the United States. A combined analysis of DPP-4 inhibitor trials suggested an increased relative risk of 79% and an absolute risk of 0.13%, which translates to 1 or 2 additional cases of acute pancreatitis for every 1000 patients treated for 2 years.28

There have been numerous postmarketing reports of severe joint pain in patients taking a DPP-4 inhibitor. Most recently, cases of bullous pemphigoid have been reported after initiation of DPP-4 inhibitor therapy.29

GLP-1 receptor agonists carry a black box warning for medullary thyroid (C-cell) tumor risk. GLP-1 receptor agonists are contraindicated in patients with a personal or family history of this cancer, although this FDA warning is based solely on observations from animal models.

In addition, GLP-1 receptor agonists can increase the risk of cholecystitis and pancreatitis. Not uncommonly, they cause gastrointestinal symptoms when first started and when the dosage is titrated upward.

Most GLP-1 receptor agonists can be used in patients with renal impairment, although data regarding their use in Stages 4 and 5 chronic kidney disease are limited.30 Semaglutide was found, in the SUSTAIN-6 trial, to be associated with an increased rate of complications of retinopathy, including vitreous hemorrhage and blindness (P = .02)31

SGLT-2 inhibitors are associated with an increased incidence of genitourinary infection, bone fracture (canagliflozin), amputation (canagliflozin), and euglycemic diabetic ketoacidosis. Agents in this class should be avoided in patients with moderate or severe renal impairment, primarily due to a lack of efficacy. They are contraindicated in patients with an estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m². (Dapagliflozin is not recommended when eGFR is < 45 mL/min/1.73 m².) These agents carry an FDA warning about the risk of acute kidney injury.30

Summing up

All glucose-lowering medications used to treat T2D are not equally effective in reducing CV complications. Recent CVOTs have uncovered evidence that certain antidiabetic agents might confer CV and all-cause mortality benefits (TABLE 2).26,27,31,14-17,19-24.

CONTINUED
### Table 2
Cardiovascular outcomes of trials of antidiabetic agents

<table>
<thead>
<tr>
<th>Medication</th>
<th>Trial</th>
<th>Median duration</th>
<th>Participants (% with CV disease)</th>
<th>Noninferior outcomes</th>
<th>Superior outcomes</th>
<th>Other outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Albglutide</td>
<td>HARMONY</td>
<td>1.6 y</td>
<td>9463 (100%)</td>
<td></td>
<td></td>
<td>Albiglutide reduced MACE-3 by 22%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No significant difference in the rate of death from any cause occurred with albiglutide compared to placebo</td>
</tr>
<tr>
<td>Dulaglutide</td>
<td>REWIND</td>
<td>5.4 y</td>
<td>9901 (31%)</td>
<td></td>
<td></td>
<td>Dulaglutide reduced MACE-3 in patients with and without CV disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Dulaglutide reduced the incidence of new-onset macroalbuminuria</td>
<td></td>
</tr>
<tr>
<td>Exenatide</td>
<td>EXSCEL</td>
<td>3.2 y</td>
<td>14,752 (73%)</td>
<td>Exenatide had no adverse effect on CV health in patients with type 2 diabetes</td>
<td></td>
<td>Exenatide showed a numerical, but nonsignificant, reduction in MACE-3</td>
</tr>
<tr>
<td>Liraglutide</td>
<td>LEADER</td>
<td>3.8 y</td>
<td>9340 (81%)</td>
<td></td>
<td></td>
<td>Liraglutide reduced primary CV-related deaths; reduced CV causes, nonfatal MI, and nonfatal stroke, as well as reduced death by any cause</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Liraglutide was associated with a reduced incidence of nephropathy compared to placebo</td>
</tr>
<tr>
<td>Lixisenatide</td>
<td>ELIXA</td>
<td>2.1 y</td>
<td>6068 (100%)</td>
<td></td>
<td>Lixisenatide was noninferior to placebo for reducing MACE-3</td>
<td></td>
</tr>
<tr>
<td>Semaglutide</td>
<td>SUSTAIN-6</td>
<td>2.1 y</td>
<td>3297 (83%)</td>
<td></td>
<td></td>
<td>Semaglutide reduced the composite MACE-3 and expanded composite outcomes (death from CV causes, nonfatal MI, nonfatal stroke, coronary revascularization and hospitalization for angina pectoris or HF)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Semaglutide was associated with a 1.2% absolute increase in retinopathy complications</td>
</tr>
<tr>
<td><strong>DIPEPTIDYL PEPTIDASE-4 INHIBITORS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alogliptin</td>
<td>EXAMINE</td>
<td>1.5 y</td>
<td>5380 (100%)</td>
<td></td>
<td></td>
<td>Alogliptin failed to reduce MACE when compared to placebo</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>There was an insignificant increase in HHF with alogliptin compared to placebo</td>
</tr>
<tr>
<td>Linagliptin</td>
<td>CARMELINA</td>
<td>2.2 y</td>
<td>6991 (57%)</td>
<td></td>
<td></td>
<td>Linagliptin failed to reduce MACE compared to placebo</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Microvascular renal outcomes and major ocular events occurred less frequently in linagliptin-treated patients</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Linagliptin failed to decrease first occurrence of end-stage renal disease, estimated glomerular filtration rate, or death caused by renal failure</td>
</tr>
</tbody>
</table>

Discussion of proposed mechanisms for CV outcome superiority of these agents is beyond the scope of this review. It is generally believed that benefits result from mechanisms other than a reduction in the serum glucose level, given the relatively short time frame of...
the studies and the magnitude of the CV benefit. It is almost certain that mechanisms of CV benefit in the 2 landmark studies—LEADER and EMPA-REG OUTCOME—are distinct from each other.32

See “When planning T2D pharmacotherapy, include newer agents that offer CV benefit,” 33-38 page 500, for a stepwise approach to treating T2D, including the role of agents that have efficacy in modifying the risk of CV disease.

### Acknowledgments
Linda Speer, MD, Kevin Phelps, DO, and Jay Shubrook, DO, provided support and editorial assistance.

### Correspondence
Robert Gotfried, DO, FAAFP, Department of Family Medicine, University of Toledo College of Medicine, 3333 Glendale Avenue, Toledo, OH 43614; Robert.gotfried@utoledo.edu.

### References

---

**Table 2**

Cardiovascular outcomes of trials of antidiabetic agents (cont’d)

<table>
<thead>
<tr>
<th>Dipeptidyl Peptidase-4 inhibitors</th>
<th>Medication</th>
<th>Trial</th>
<th>Median duration</th>
<th>Participants (% with CV disease)</th>
<th>Noninferior outcomes</th>
<th>Superior outcomes</th>
<th>Other outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saxagliptin</td>
<td>Saxagliptin</td>
<td>SAVOR-TIMI 53&lt;sup&gt;a&lt;/sup&gt;</td>
<td>2.1 y</td>
<td>16,492 (78%)</td>
<td>Saxagliptin failed to reduce MACE compared to placebo</td>
<td>Saxagliptin was associated with a 0.7% absolute increase in the risk of HHF</td>
<td></td>
</tr>
<tr>
<td>Sitagliptin</td>
<td>Sitagliptin</td>
<td>TECOS&lt;sup&gt;11&lt;/sup&gt;</td>
<td>2.8 y</td>
<td>14,671 (74%)</td>
<td>Sitagliptin failed to reduce MACE compared to placebo</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium–Glucose Cotransporter-2 inhibitors</td>
<td>Canagliflozin</td>
<td>CANVAS&lt;sup&gt;23&lt;/sup&gt;</td>
<td>2.4 y</td>
<td>10,142 (71%)</td>
<td>Canagliflozin reduced MACE-3 by 14%</td>
<td>Canagliflozin did not alter the occurrence of CV death or overall mortality</td>
<td></td>
</tr>
<tr>
<td>Dapagliflozin</td>
<td>Dapagliflozin</td>
<td>DECLARE-TIMI 58&lt;sup&gt;24&lt;/sup&gt;</td>
<td>4.2 y</td>
<td>17,160 (40.5%)</td>
<td>Dapagliflozin failed to reduce MACE-3 outcomes</td>
<td>Dapagliflozin reduced the risk of CV death or HHF by 17%</td>
<td></td>
</tr>
<tr>
<td>Empagliflozin</td>
<td>EMPA-REG OUTCOME&lt;sup&gt;22&lt;/sup&gt;</td>
<td>3.1 y</td>
<td>7020 (99%)</td>
<td>Empagliflozin reduced MACE-3 by 14% compared to placebo</td>
<td>A 32% decrease in all-cause mortality, 38% reduction in CV death, and 35% reduction in HHF were documented</td>
<td>Empagliflozin did not alter the occurrence of nonfatal MI or stroke</td>
<td></td>
</tr>
</tbody>
</table>

CV, cardiovascular; HF, heart failure; HHF, hospitalization for heart failure; MACE, major adverse cardiovascular event composite endpoint; MACE-3, 3-point major adverse cardiovascular event composite endpoint; MI, myocardial infarction.

<sup>a</sup>Since 2008.


